Caitong International Asset Management Co. Ltd Sells 856 Shares of LivaNova PLC $LIVN

Caitong International Asset Management Co. Ltd reduced its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 58.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 613 shares of the company’s stock after selling 856 shares during the quarter. Caitong International Asset Management Co. Ltd’s holdings in LivaNova were worth $28,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. CWM LLC lifted its position in shares of LivaNova by 52.3% during the 1st quarter. CWM LLC now owns 871 shares of the company’s stock worth $34,000 after buying an additional 299 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of LivaNova by 182.5% during the 2nd quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock worth $28,000 after buying an additional 407 shares during the last quarter. Central Pacific Bank Trust Division lifted its position in shares of LivaNova by 9.5% during the 2nd quarter. Central Pacific Bank Trust Division now owns 4,827 shares of the company’s stock worth $217,000 after buying an additional 420 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of LivaNova by 2.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 21,000 shares of the company’s stock worth $817,000 after buying an additional 500 shares during the last quarter. Finally, Hsbc Holdings PLC lifted its position in shares of LivaNova by 13.4% during the 1st quarter. Hsbc Holdings PLC now owns 6,666 shares of the company’s stock worth $258,000 after buying an additional 790 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

LIVN has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of LivaNova in a research report on Saturday. Barclays upped their target price on LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. The Goldman Sachs Group set a $55.00 target price on LivaNova and gave the stock a “neutral” rating in a report on Wednesday, October 1st. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 target price on shares of LivaNova in a report on Wednesday, September 3rd. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, LivaNova has an average rating of “Moderate Buy” and an average target price of $59.71.

LivaNova Trading Up 0.8%

Shares of LIVN stock opened at $54.89 on Monday. The stock has a market cap of $3.00 billion, a price-to-earnings ratio of -14.11 and a beta of 0.95. The stock has a 50-day moving average of $54.53 and a 200-day moving average of $47.12. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $58.91.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.21. The company had revenue of $352.50 million during the quarter, compared to analysts’ expectations of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The business’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.93 earnings per share. On average, equities research analysts forecast that LivaNova PLC will post 2.85 earnings per share for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.